73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
Engineering the immune system to tackle glioblastoma

Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar

Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar
Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm
EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract
Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

byEmory UniversityHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0A targeted therapy for children with high-risk Hodgkin l

Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

byEmory UniversityHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0A targeted therapy for children with high-risk Hodgkin l
Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.
Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

by NRG OncologyCredit: CC0 Public DomainLung cancer is the leading cause of cancer death in the United States and approximately 75-80 percent of all cases are non-small cell lung cancer (NSCLC). Of th

Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

by NRG OncologyCredit: CC0 Public DomainLung cancer is the leading cause of cancer death in the United States and approximately 75-80 percent of all cases are non-small cell lung cancer (NSCLC). Of th
Low long-term risk of breast cancer recurrence after nipple-sparing mastectomy

Low long-term risk of breast cancer recurrence after nipple-sparing mastectomy

byWolters Kluwer HealthCredit: Pixabay/CC0 Public DomainNipple-sparing mastectomy (NSM)—an increasingly popular option for women undergoing treatment for breast cancer—not only achieves good cos

Low long-term risk of breast cancer recurrence after nipple-sparing mastectomy

byWolters Kluwer HealthCredit: Pixabay/CC0 Public DomainNipple-sparing mastectomy (NSM)—an increasingly popular option for women undergoing treatment for breast cancer—not only achieves good cos
Scalp Cooling for Chemo Hair Loss Strikes Out With Patients

Scalp Cooling for Chemo Hair Loss Strikes Out With Patients

M. Alexander Otto, PA, MMSTOPLINE:Most women withbreast cancerwho received scalp cooling did not perceive benefits in preventing hair loss, overall quality of life, body image, and other o

Scalp Cooling for Chemo Hair Loss Strikes Out With Patients

M. Alexander Otto, PA, MMSTOPLINE:Most women withbreast cancerwho received scalp cooling did not perceive benefits in preventing hair loss, overall quality of life, body image, and other o
New factor in the development of hereditary kidney cancer discovered

New factor in the development of hereditary kidney cancer discovered

by Gabriele Meseg-Rutzen,University of CologneHira-andFh1-deficient cells promote tumor initiation, growth, and invasion in vivo.(A) Scheme of xenograft injections in the flank of nu

New factor in the development of hereditary kidney cancer discovered

by Gabriele Meseg-Rutzen,University of CologneHira-andFh1-deficient cells promote tumor initiation, growth, and invasion in vivo.(A) Scheme of xenograft injections in the flank of nu
Understanding lung cancer

Understanding lung cancer

by Jason HowlandCredit: Pixabay/CC0 Public DomainNovember is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths worldwide. Each year, more people die from lung cancer than

Understanding lung cancer

by Jason HowlandCredit: Pixabay/CC0 Public DomainNovember is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths worldwide. Each year, more people die from lung cancer than
Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate
Multimodal genomic analyses predict response to immunotherapy in lung cancer patients

Multimodal genomic analyses predict response to immunotherapy in lung cancer patients

by Amy Mone,Johns Hopkins University School of MedicineLung cancer. Credit: Jennifer Fairman and Valsamo Anagnostou, Johns Hopkins UniversityResearchers at Johns Hopkins Kimmel Cancer Center, th

Multimodal genomic analyses predict response to immunotherapy in lung cancer patients

by Amy Mone,Johns Hopkins University School of MedicineLung cancer. Credit: Jennifer Fairman and Valsamo Anagnostou, Johns Hopkins UniversityResearchers at Johns Hopkins Kimmel Cancer Center, th